Improving risk stratification in patients with prostate cancer managed by active surveillance: A nomogram predicting the risk of biopsy progression

BJU International

Volumn 112, Issue 1, 2013, Pages 39-44

  Iremashvili, Viacheslav ^a   Burdick Will, Joshua ^a   Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

active surveillance; nomogram; prostate biopsy; prostate cancer; PSA density

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CLINICAL ASSESSMENT TOOL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RACE; RISK ASSESSMENT; RISK FACTOR; TUMOR BIOPSY;

ADULT; AGED; BIOPSY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84879124352     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12112     Document Type: Article

References (19)

1. Dall'era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012; 62: 976-983
2. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-2190
3. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC,. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185: 471-476
4. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011; 29: 2795-2800
5. Bul M, van den Bergh RC, Rannikko A, et al. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol 2012; 61: 370-377
6. Vickers AJ, Cronin AM,. Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology 2010; 76: 1298-1301
7. Iremashvili V, Manoharan M, Rosenberg DL, Soloway MS,. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models. BJU Int 2012; doi: 10.1111/j.1464-410X. 2012.11127.x
8. Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB,. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183: 1779-1785
9. Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS,. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int 2013; 111: 396-403
10. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-2816
11. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011; 185: 1656-1660
12. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374
13. Wolters T, Roobol MJ, van, Leeuwen PJ, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121-125
14. van den Bergh RC, Steyerberg EW, Khatami A, et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2010; 116: 1281-1290
15. Nagarajan R, Margolis D, Raman S, et al. MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging 2012; 36: 697-703
16. Ouzzane A, Puech P, Villers A,. MRI and surveillance. Curr Opin Urol 2012; 22: 231-236
17. van Poppel H, Haese A, Graefen M, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012; 109: 360-366
18. Montironi R, Egevad L, Bjartell A, Berney DM,. Role of histopathology and molecular markers in the active surveillance of prostate cancer. Acta Oncol 2011; 50 (Suppl. 1): 56-60
19. McGuire BB, Helfand BT, Kundu S, et al. Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance. BJU Int 2012; 110: 338-343